However, IL-17A blockade led to significantly improved whole-body insulin sensitivity (Figure 4D), and it reduced hepatic steatosis and LD diameter to levels comparable with CD11cWT littermates (Figure 4, E–G). This evidence concerns the gene IL17A and fatty liver disease.